New hope for ALS patients denied other trials

NCT ID NCT07088159

Summary

This program provides the experimental drug SPG302 to adults with ALS who cannot join other clinical trials. It aims to assess the drug's safety and whether it helps slow the disease. Participants must have some remaining lung function and be on stable ALS medications if currently taking them.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atlantic Health

    AVAILABLE

    Summit, New Jersey, 07901, United States

    Contact Email: •••••@•••••

  • Baylor College of Medicine

    AVAILABLE

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • California Pacific Medical Center

    AVAILABLE

    San Francisco, California, 94109, United States

    Contact Email: •••••@•••••

  • Cedar-Sinai Medical Center

    AVAILABLE

    Los Angeles, California, 90048, United States

    Contact Email: •••••@•••••

  • Columbia University Medical Center

    AVAILABLE

    New York, New York, 10032, United States

    Contact Email: •••••@•••••

  • Dartmouth-Hitchcock Medical Center

    AVAILABLE

    Lebanon, New Hampshire, 03756, United States

    Contact Email: •••••@•••••

  • Kaiser Permanente Los Angeles

    AVAILABLE

    Los Angeles, California, 90027, United States

    Contact Email: •••••@•••••

  • Massachusetts General Hospital

    AVAILABLE

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Mayo Scottsdale

    AVAILABLE

    Scottsdale, Arizona, 85259, United States

    Contact Email: •••••@•••••

  • Nova Southeastern University

    AVAILABLE

    Davie, Florida, 33314, United States

    Contact Email: •••••@•••••

  • Synapticure

    AVAILABLE

    Chicago, Illinois, 60640, United States

    Contact Email: •••••@•••••

  • Thomas Jefferson University

    AVAILABLE

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

  • University of Alabama Birmingham

    AVAILABLE

    Birmingham, Alabama, 35233, United States

    Contact Email: •••••@•••••

  • VCU ALS Research Group

    AVAILABLE

    Henrico, Virginia, 23233, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.